MRD is rapidly emerging as a key biomarker in therapy development and patient care, however, key challenges remain. Personalis is committed to addressing some of the most pressing needs in the liquid biopsy space.

In this webinar attendees will learn about the role of next-generation liquid biopsy assays in enabling:

Earlier detection of disease recurrence
Utility in more disease indications, and at earlier stages of disease
Patient enrichment, screening/enrollment and surrogate endpoint analysis for clinical trials
Higher resolution variant tracking
Combining plasma and tissue analyses
Register to learn how liquid biopsy assays go beyond recurrence detection in post-diagnosis cancer management.

https://xtalks.dryfta.com/?eid=38&pid=4